Zimmer Biomet (NYSE:ZBH) Posts Quarterly Earnings Results

Zimmer Biomet (NYSE:ZBH) posted its quarterly earnings results on Wednesday. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02, FiscalAI reports. The firm had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2.04 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period last year, the company earned $1.90 earnings per share.

Here are the key takeaways from Zimmer Biomet’s conference call:

• Zimmer Biomet reported 3.7% constant-currency sales growth, with hips up 7%, S.E.T. up 7.1%, and technology, data, bone cement, and surgical up 13%. The company said two-thirds of its portfolio grew at upper-single-digit or double-digit rates.
• The company raised its 2026 organic constant-currency sales growth outlook to 3%–3.5% and adjusted EPS guidance to $8.50–$8.60. It cited stronger-than-expected performance and expects full-year free cash flow to grow 9%–11%.
• Knee sales declined 2.6% in constant currency, amid U.S. sales-force transition and competitive pressure, with China also weighing on results. Management expects near-term pressure to continue and acknowledged the transition’s final stage carries higher risk.
• Zimmer Biomet plans to submit Monogram’s 510(k) application soon and expects a potential launch in the first half of 2027, ahead of its prior timeline; the timing remains subject to FDA approval. Management views the system as a potential growth catalyst alongside its existing robotics offerings.
• Third-quarter adjusted EPS was flat at $1.90, while adjusted operating margin fell 140 basis points to 25.1%, reflecting investment in the U.S. commercial organization and higher manufacturing costs.

Zimmer Biomet Price Performance

NYSE ZBH traded up $13.46 during trading on Wednesday, reaching $110.52. The company’s stock had a trading volume of 3,688,141 shares, compared to its average volume of 2,247,609. The stock has a market capitalization of $21.08 billion, a PE ratio of 26.89, a P/E/G ratio of 2.34 and a beta of 0.50. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The firm has a fifty day moving average of $94.71 and a 200 day moving average of $91.78. Zimmer Biomet has a one year low of $79.12 and a one year high of $112.55.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date was Wednesday, September 30th. Zimmer Biomet’s payout ratio is presently 23.36%.

Key Stories Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter sales were $2.063 billion, up 3.1% year over year, while adjusted diluted EPS of $1.90 beat analyst estimates. Zimmer Biomet third-quarter results
• Positive Sentiment: The company raised its full-year 2026 growth outlook. Strong hip and S.E.T. sales supported the improved view, adding to the positive earnings reaction. Zacks outlook and sales summary
• Negative Sentiment: Knee-market weakness and margin pressure remain headwinds. Adjusted EPS was unchanged from a year earlier, while reported diluted EPS fell 13.8% to $1.00. Benzinga earnings coverage

Insider Transactions at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. Company insiders own 1.28% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on ZBH shares. Royal Bank Of Canada raised their target price on Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Robert W. Baird set a $104.00 price target on Zimmer Biomet in a research report on Thursday, August 6th. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 25th. Argus restated a “buy” rating and issued a $125.00 price objective on shares of Zimmer Biomet in a research report on Thursday, October 22nd. Finally, Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $104.47.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.